Medicortex Finland Oy Announces Issuance of a Patent for Brain Injury Biomarker
16.4.2020 09:55:00 EEST | Business Wire | Press release
Medicortex Finland Oy, an innovative biopharmaceutical company focused on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), today announced that the European Patent Office (EPO) has issued a patent covering company’s new diagnostic kit technology.
“We are extremely pleased with the growth of the patent portfolio related to the TBI testing. This new issuance continues to expand the intellectual property portfolio covering methods to be used for detection of concussion biomarkers. The issuance of this patent is another step in the development of a robust patent portfolio relating to a new strategy to help identify mild TBI” said Dr. Harel Adrian, Chief Executive Officer of Medicortex.
Medicortex is currently developing a rapid diagnostic kit for detection of concussion and mild traumatic brain injury from urine or saliva. The kit is based on specific biomarkers that the company has discovered from body fluids following brain injury. Such a rapid test will fulfill the urgent need to improve the detection of brain injury especially in mild cases – which are potentially harmful but admittedly difficult to diagnose with the contemporary means. The issued patent covers the core technology and method of utilizing glycan-based biomarkers for detection of mild traumatic brain injury, which is presently the company’s main development program.
Medicortex’s patent portfolio comprises of biomarkers for brain injury diagnostics and drug candidates for halting the progression of brain injury. All innovations have been developed by the company. The comprehensive patent coverage secures exclusivity to develop the products, and the company’s strategy is to actively seek new patentable innovations from its biomarker and drug development programs.
About Medicortex
Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect the presence of a head injury. The company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. Medicortex was established by an Israeli neurobiologist Adrian Harel (Ph.D., MBA) in 2014, and the company is based in Turku, Finland.
Key words: brain injury, head injury, concussion, diagnostics, TBI, early detection, trauma, clinical trial, new patent
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Medicortex assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005854/en/
Contact information
Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358 (0) 400 488 817
adrian.harel@medicortex.fi
http://www.medicortex.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netmore and Cibicom Enter Strategic Partnership for Denmark and Introduce Unified Roaming Across the Nordics15.9.2026 09:00:00 EEST | Press release
Netmore Group, the leading network operator for Massive IoT, today announced that Cibicom has selected Netmore’s Operator Platform-as-a-Service (PaaS) to operate, optimize, and scale its nationwide LoRaWAN® network for Internet of Things (IoT) deployments. Cibicom is the largest LoRaWAN network operator in Denmark and provides critical communication infrastructure for nationwide broadcast and LTE450 services as well as tier 3 data center solutions and B2B fiber connectivity. The partnership means that Cibicom will replace its existing LoRaWAN Network Server with Netmore’s ThingPark Platform and that the Parties will work strategically together to ensure Danish customers can benefit from comprehensive and reliable LoRaWAN connectivity across Denmark. By leveraging Netmore's carrier-grade platform, Cibicom gains enhanced network scalability, seamless roaming, and high-availability features, improving its delivery of reliable, cost-effective connectivity to customers in utilities, energy
PSG Equity Holds Final Close of Third European Fund at Over €4.4 Billion15.9.2026 09:00:00 EEST | Press release
PSG Equity (“PSG”), a leading growth equity firm that specializes in partnering with software and technology-enabled services companies to drive transformational growth, today announced the final close of PSG Europe III (“PSGE III” or the “fund”) at over €4.4 billion in total committed capital. The fund reached its hard cap, receiving strong support from new and returning investors. PSGE III surpasses its €2.6 billion predecessor fund, which held its final close in October 2023. The Europe-focused fund saw commitments from state pension funds, sovereign wealth funds, insurance companies, family offices and high net worth individuals. PSGE III will continue the firm’s strategy of partnering with ambitious European software and technology companies, helping them to scale up as they seek to become pan-European category leaders with global reach. The fund aims to support businesses that are harnessing AI to redefine enterprise software and the next generation of AI-native companies, with r
Adabas & Natural Appoints Hans Roth as Chief Executive Officer15.9.2026 09:00:00 EEST | Press release
Adabas & Natural (A&N) today announced the appointment of Hans Roth as Chief Executive Officer, effective November 1. The appointment marks a defining moment as A&N enters its next chapter positioned for sustained, accelerating growth. Following the carveout of webMethods, StreamSets, Alfabet, Cumulocity, TrendMiner, and ARIS from Software GmbH, A&N is now back to its original roots as the multi-decade leading mission-critical database and infrastructure software suite. Roth joins from Red Hat, where he most recently served as Senior Vice President and General Manager for Europe, Middle East, and Africa (EMEA) and previously led Red Hat’s EMEA services business. Before joining Red Hat, Roth served as Vice President of the service delivery unit at Hewlett-Packard Enterprise for central Europe. “I’m thrilled to help build on A&N’s decades-strong foundation of mission-critical reliability and to drive continued growth, serving a customer base that entrusts us with operating the systems on
TreviPay Partners with Dynatos to Add e-Invoicing Capabilities to its B2B Payments Infrastructure15.9.2026 08:00:00 EEST | Press release
TreviPay, a global B2B payments infrastructure partner, today announced a partnership with Dynatos to expand e-invoicing capabilities for TreviPay clients operating across Europe and other markets. Through the partnership, Dynatos Routty Cloud proposition will provide embedded e-invoicing technology and compliance support, helping TreviPay clients exchange invoices across different formats, networks and country requirements in Europe and other global markets. E-invoicing requirements continue to expand across Europe and other global markets, adding complexity for businesses managing invoices across more than 60 countries with mandates announced or already in place. At the same time, invoicing has become an increasingly important part of the B2B buyer experience. TreviPay research found 68% of B2B buyers are more likely to choose a supplier offering invoice terms, up from 51% in 2023. As businesses expand across markets, delivering the invoicing experience buyers expect also requires na
Meiji Group to Showcase Japanese-Quality CMO/CDMO Services and a Global Manufacturing Network at CPHI Milan 202615.9.2026 08:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (HQ: Chuo-ku, Tokyo; President and CEO: Toshiaki Nagasato) will debut as the Meiji Group’s Pharmaceutical Segment at CPHI Milan 2026, at Fiera Milano, Milan, Italy, October 6–8, 2026. At the exhibition, the Meiji Group’s Pharmaceuticals Segment will showcase 80 years of expertise in Japanese standard quality control, manufacturing, and supply network from Japan to Europe, India, and Southeast Asia. It will also highlight group-wide contract manufacturing, from development to supply, tailored to customer needs. Through the exhibition, Meiji Seika Pharma aims to raise global awareness of the Meiji Group’s Pharmaceutical Segment, its brands, capabilities, production capacity, and contract manufacturing services, and to forge new global partnerships to expand its CMO/CDMO business. “CPHI Milan 2026” Exhibition Overview Exhibition Name: CPHI Milan 2026 Dates: October 6 (Tue) – 8 (Thu), 2026 Venue: Fiera Milano (Milan, Italy) Exhibition Area: CMO Area Booth Numbe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom